Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
DCISionRT(R) by PreludeDx(TM) Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare and Medicaid Services
LAGUNA HILLS, Calif., March 28, 2023 -- (Healthcare Sales & Marketing Network) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Med... Diagnostics, Oncology PreludeDx, DCISionRT test, ductal carcinoma in situ (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news
New BAP1 Finding Could Be Key to Regulating Mesothelioma
Mesothelioma is a rare cancer most often caused by exposure to asbestos fibers. Our researchers at the University of Hawaii Cancer Center have discovered how asbestos causes mesothelioma, which we linked mainly to the protein HMGB1.
After several years of studying a unique mesothelioma epidemic in Cappadocia, Turkey, we noted that in certain families, up to 50% of family members developed mesothelioma. We demonstrated that susceptibility to mesothelioma was transmitted genetically from one generation to the next.
Following this discovery, several U.S. families with multiple mesothelioma cases contacted us...
Source: Asbestos and Mesothelioma News - March 9, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Alembic Pharma gets USFDA nod to market generic cancer drug
Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2023 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news
Half of DCIS-treated women don't get ongoing imaging surveillance
More than half of women treated for ductal carcinoma in situ (DCIS) do not consistentl...Read more on AuntMinnie.comRelated Reading:
Is palpable DCIS more aggressive than screen-detected?
Ultrafast MRI shows promise in predicting DCIS upstaging
Screening breast imaging findings differ between Black and white women
Ultrasound guidance effective in DCIS surgery
DWI-MRI predicts whether women's DCIS will upstage after surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 11, 2023 Category: Radiology Source Type: news
Is palpable DCIS more aggressive than screen-detected?
Palpable ductal carcinoma in situ (DCIS) does not have significant recurrenc...Read more on AuntMinnie.comRelated Reading:
Ultrafast MRI shows promise in predicting DCIS upstaging
Ultrasound guidance effective in DCIS surgery
Researchers use microscopy technique to map breast tumor cells
AI helps identify breast lesion subtypes
Breast cancer overdiagnosis rates are low in mammography screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2022 Category: Radiology Source Type: news
Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news
The Increasing Role of SOX10 in Diagnostic Breast Pathology The Increasing Role of SOX10 in Diagnostic Breast Pathology
A recent study confirms the usefulness of the transcription factor SOX10 in the practice of breast pathology, primarily as a marker for triple-negative breast carcinoma.American Journal of Clinical Pathology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 24, 2022 Category: Allergy & Immunology Tags: Pathology & Lab Medicine Journal Article Source Type: news
Ultrasound guidance effective in DCIS surgery
Ultrasound-guided surgery in women with ductal carcinoma in situ (DCIS) is effectiv...Read more on AuntMinnie.comRelated Reading:
Breast ultrasound valuable in low-income countries
AI predicts breast cancer risk from normal ultrasound images
Lymphadenopathy on breast ultrasound lasts longer than reported
Artificial intelligence for breast ultrasound
Ultrasound jostles for bigger role in screening dense breasts (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2022 Category: Radiology Source Type: news
